Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Pseudoporphyria is characterized by erythema, blistering, and scarring on sun-exposed skin. Nonsteroidal antiinflammatory drugs (NSAIDs) are implicated in the etiology of this condition. In a 1-year prospective study of children attending the pediatric rheumatology clinic in Edinburgh we found a prevalence of pseudoporphyria of 10.9% in children taking NSAIDs for juvenile idiopathic arthritis. Naproxen was the most commonly implicated NSAID, independent of dosage. Blue/gray eye color was an independent risk factor for the development of pseudoporphyria. We would advise caution in prescribing naproxen in these children to prevent disfiguring facial scarring.

Original publication

DOI

10.1046/j.1525-1470.2000.01827.x

Type

Journal article

Journal

Pediatr dermatol

Publication Date

11/2000

Volume

17

Pages

480 - 483

Keywords

Adolescent, Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Juvenile, Child, Child, Preschool, Cohort Studies, Female, Humans, Male, Naproxen, Porphyrias, Prevalence, Prospective Studies, Risk Factors, Skin